ultra-long acting
GSK wins FDA approval for ultra-long-acting asthma drug Exdensur (depemokimab)
GSK; Exdensur; depemokimab; FDA approval; severe asthma; ultra-long-acting biologic; twice-yearly dosing; type 2 inflammation; eosinophilic phenotype; IL-5 inhibitor